Down to the state of journalism again, but not one mention of the fact that MNTA (An American company) has raised the bar in the quality of generic that is possible to be created as MNTA has created a precise copy of the name brand drug, and insured its quality to at least the same standard as the name brand drug, whereas Teva (an Israeli company) is trying to push onto the market a generic knock-off lovenox that is not really the same, and which could endanger the health and welfare of patients.
The way the article reads you'd think there was no difference between the applications.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.